دورية أكاديمية
Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.
| العنوان: | Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial. |
|---|---|
| المؤلفون: | Pineda-Peña AC; Global Clinical Immunology, Sanofi, Campus Mérieux, Marcy l'Etoile, France., Jiang Q; Global Clinical Immunology, Sanofi, Campus Mérieux, Marcy l'Etoile, France., Petit C; Global Clinical Immunology, Sanofi, Campus Mérieux, Marcy l'Etoile, France., Korejwo-Peyramond J; Patient Safety & Pharmacovigilance, Sanofi, Campus Carteret, Lyon, France., Donazzolo Y; Eurofins, Optimed, Gieres, France., Latreille M; Eurofins, Optimed, Gieres, France., Homery MC; Biotrial, Rennes, France., Babin V; Global Clinical Immunology, Sanofi, Campus Mérieux, Marcy l'Etoile, France., Benamor S; Global Clinical Immunology, Sanofi, Campus Mérieux, Marcy l'Etoile, France., Pichon S; Global Clinical Immunology, Sanofi, Campus Mérieux, Marcy l'Etoile, France., Guinet-Morlot F; Global Clinical Immunology, Sanofi, Campus Mérieux, Marcy l'Etoile, France., Minutello AM; Global Clinical Immunology, Sanofi, Campus Mérieux, Marcy l'Etoile, France. |
| المصدر: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1748-1756. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: Chicago, IL : The University of Chicago Press, c1992- |
| مواضيع طبية MeSH: | Rabies Vaccines*/immunology , Rabies Vaccines*/administration & dosage , Rabies Vaccines*/adverse effects , Rabies*/prevention & control , Post-Exposure Prophylaxis*/methods , Antibodies, Viral*/blood , Antibodies, Neutralizing*/blood , Rabies virus*/immunology, Humans ; Adult ; Male ; Female ; Double-Blind Method ; Middle Aged ; Young Adult ; Vero Cells ; France ; Animals ; Chlorocebus aethiops ; Adolescent ; Immunogenicity, Vaccine ; Healthy Volunteers |
| مستخلص: | Background: A next-generation Vero cell rabies vaccine (PVRV-NG2) was developed using the same Pitman-Moore strain as in the licensed purified Vero cell vaccine (PVRV; Verorab) and the human diploid cell vaccine (HDCV; Imovax Rabies®). Methods: This dual-center, modified, double-blind, phase 3 study evaluated the immunogenic non-inferiority and safety of PVRV-NG2 with and without concomitant intramuscular human rabies immunoglobulin (HRIG) versus PVRV + HRIG and HDCV + HRIG in a simulated post-exposure prophylaxis (PEP) regimen. Healthy adults ≥18 years old (N = 640) were randomized 3:1:1:1 to PVRV-NG2 + HRIG, PVRV + HRIG, HDCV + HRIG, or PVRV-NG2 alone (administered as single vaccine injections on days [D] 0, D3, D7, D14, and 28, with HRIG on D0 in applicable groups). Rabies virus neutralizing antibodies (RVNA) titers were assessed pre- (D0) and post-vaccination (D14, D28, and D42) using the rapid fluorescent focus inhibition test. Non-inferiority, based on the proportion of participants achieving RVNA titers ≥0.5 IU/mL (primary objective), was demonstrated if the lower limit of the 95% CI of the difference in proportions between PVRV-NG2 + HRIG and PVRV + HRIG/HDCV + HRIG was >-5% at D28. Safety was assessed up to 6 months after the last injection. Results: Non-inferiority of PVRV-NG2 + HRIG compared with PVRV + HRIG and HDCV + HRIG was demonstrated. Nearly all participants (99.6%, PVRV-NG2 + HRIG; 100%, PVRV + HRIG; 98.7%, HDCV + HRIG; 100%, PVRV-NG2 alone) achieved RVNA titers ≥0.5 IU/mL at D28. Geometric mean titers were similar between groups with concomitant HRIG administration at all time points. Safety profiles were similar between PVRV-NG2 and comparator vaccines. Conclusions: In a simulated PEP setting, PVRV-NG2 + HRIG showed comparable immunogenicity and safety to current standard-of-care vaccines. Clinical Trials Registration: NCT03965962. Competing Interests: Potential conflicts of interest. A. C. P. P., Q. J., C. P., J. K. P., V. B., S. B., S. P., F. G. M., and A. M. M. are employees of Sanofi and may hold shares and/or stock options in the company. Y. D. reports other financial or nonfinancial interests as investigator and CEO of 1 of the investigation sites. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.) |
| References: | Travel Med Infect Dis. 2007 Nov;5(6):327-48. (PMID: 17983973) Viruses. 2021 Jul 31;13(8):. (PMID: 34452381) Hum Vaccin Immunother. 2022 Dec 31;18(1):2027714. (PMID: 35192787) Vaccine. 2022 Aug 19;40(35):5170-5178. (PMID: 35906106) Vaccine. 2017 Jul 24;35(33):4064-4071. (PMID: 28647170) PLoS Negl Trop Dis. 2015 Apr 16;9(4):e0003709. (PMID: 25881058) Hum Vaccin Immunother. 2016;12(1):239-43. (PMID: 26836329) Vaccine. 2017 Feb 7;35(6):966-971. (PMID: 28081969) Clin Infect Dis. 2012 Jul;55(2):201-5. (PMID: 22550115) World Health Organ Tech Rep Ser. 2013;(982):1-139, back cover. (PMID: 24069724) Vaccine. 2022 Aug 5;40(33):4780-4787. (PMID: 35778281) Acta Clin Belg. 2021 Apr;76(2):91-97. (PMID: 31483218) Hum Vaccin Immunother. 2023 Dec 15;19(3):2275453. (PMID: 37921410) Biologicals. 2017 Mar;46:124-129. (PMID: 28214171) Vaccine. 2018 Sep 5;36(37):5500-5503. (PMID: 30107991) JAMA. 1971 Sep 27;217(13):1825-31. (PMID: 4105880) Clin Infect Dis. 2018 Jan 18;66(3):387-395. (PMID: 29020321) MMWR Recomm Rep. 2010 Mar 19;59(RR-2):1-9. (PMID: 20300058) Hum Vaccin Immunother. 2020;16(2):452-459. (PMID: 31549899) Stat Med. 1998 Apr 30;17(8):873-90. (PMID: 9595617) Immunol Rev. 2020 Jan;293(1):253-269. (PMID: 31605396) Vaccine. 2013 Apr 26;31(18):2295-301. (PMID: 23510665) PLoS Negl Trop Dis. 2010 Mar 09;4(3):e595. (PMID: 20231877) J Immunol Methods. 2019 Nov;474:112626. (PMID: 31228423) Sci Rep. 2020 Jun 18;10(1):9893. (PMID: 32555434) Hum Vaccin Immunother. 2021 Jul 3;17(7):2090-2096. (PMID: 33563087) Sci Rep. 2022 Apr 21;12(1):6570. (PMID: 35449223) Bull World Health Organ. 1973 May;48(5):535-41. (PMID: 4544144) Hum Vaccin Immunother. 2017 Jul 3;13(7):1531-1538. (PMID: 28406752) Pharmacotherapy. 2021 Aug;41(8):644-648. (PMID: 34224157) Vaccine. 2013 Dec 5;31(50):5940-7. (PMID: 24148575) Expert Rev Vaccines. 2018 Jun;17(6):525-545. (PMID: 29939085) |
| معلومات مُعتمدة: | Sanofi |
| فهرسة مساهمة: | Keywords: PVRV-NG2; immunogenicity; post-exposure prophylaxis; rabies; safety |
| سلسلة جزيئية: | ClinicalTrials.gov NCT03965962 |
| المشرفين على المادة: | 0 (Rabies Vaccines) 0 (Antibodies, Viral) 0 (Antibodies, Neutralizing) |
| تواريخ الأحداث: | Date Created: 20240313 Date Completed: 20240613 Latest Revision: 20240615 |
| رمز التحديث: | 20240615 |
| مُعرف محوري في PubMed: | PMC11175674 |
| DOI: | 10.1093/cid/ciae137 |
| PMID: | 38478634 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciae137 |